$LSTA
LISATA THERAPEUTICS, INC.

2021 Q1 Form 10-Q Financial Statement

#000032001721000067 Filed on May 06, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.010M $2.558M
YoY Change 17.67% 0.16%
% of Gross Profit
Research & Development $5.076M $1.499M
YoY Change 238.63% -26.45%
% of Gross Profit
Depreciation & Amortization $20.00K $20.00K
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $8.086M $4.057M
YoY Change 99.31% -11.65%
Operating Profit -$8.086M -$4.057M
YoY Change 99.31% -11.65%
Interest Expense $20.00K $70.00K
YoY Change -71.43%
% of Operating Profit
Other Income/Expense, Net $23.00K $71.00K
YoY Change -67.61% -68.72%
Pretax Income -$8.063M -$3.990M
YoY Change 102.08% -8.7%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$8.063M -$3.990M
YoY Change 102.08% -8.63%
Net Earnings / Revenue
Basic Earnings Per Share -$0.19 -$0.38
Diluted Earnings Per Share -$0.19 -$0.38
COMMON SHARES
Basic Shares Outstanding 42.12M shares 10.62M shares
Diluted Shares Outstanding 42.12M shares 10.62M shares

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $111.5M $20.75M
YoY Change 437.53% -45.93%
Cash & Equivalents $28.74M $20.75M
Short-Term Investments $82.77M $0.00
Other Short-Term Assets $2.500M $500.0K
YoY Change 400.0% -61.54%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $114.0M $21.21M
YoY Change 437.74% -46.51%
LONG-TERM ASSETS
Property, Plant & Equipment $41.00K $87.00K
YoY Change -52.87% -41.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $533.0K $847.0K
YoY Change -37.07% -43.31%
Total Long-Term Assets $574.0K $934.0K
YoY Change -38.54% -43.12%
TOTAL ASSETS
Total Short-Term Assets $114.0M $21.21M
Total Long-Term Assets $574.0K $934.0K
Total Assets $114.6M $22.14M
YoY Change 417.65% -46.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.315M $64.00K
YoY Change 3517.19% -88.43%
Accrued Expenses $2.123M $4.556M
YoY Change -53.4% 0.18%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.438M $4.620M
YoY Change -3.94% -9.43%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $155.0K $536.0K
YoY Change -71.08% -69.0%
Total Long-Term Liabilities $155.0K $536.0K
YoY Change -71.08% -69.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.438M $4.620M
Total Long-Term Liabilities $155.0K $536.0K
Total Liabilities $4.593M $5.156M
YoY Change -10.92% -24.51%
SHAREHOLDERS EQUITY
Retained Earnings -$433.6M -$421.4M
YoY Change 2.9% 4.72%
Common Stock $60.00K $11.00K
YoY Change 445.45% 10.0%
Preferred Stock
YoY Change
Treasury Stock (at cost) $708.0K $708.0K
YoY Change 0.0% 0.0%
Treasury Stock Shares 11.08K shares 11.08K shares
Shareholders Equity $110.3M $17.24M
YoY Change
Total Liabilities & Shareholders Equity $114.6M $22.14M
YoY Change 417.65% -46.38%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$8.063M -$3.990M
YoY Change 102.08% -8.63%
Depreciation, Depletion And Amortization $20.00K $20.00K
YoY Change 0.0% 0.0%
Cash From Operating Activities -$7.975M -$4.241M
YoY Change 88.05% -22.69%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $2.000K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$65.09M $11.10M
YoY Change -686.4% 27.0%
Cash From Investing Activities -$65.09M $11.10M
YoY Change -686.29% 27.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $85.46M $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $85.30M -$148.0K
YoY Change -57733.11% -117.01%
NET CHANGE
Cash From Operating Activities -$7.975M -$4.241M
Cash From Investing Activities -$65.09M $11.10M
Cash From Financing Activities $85.30M -$148.0K
Net Change In Cash $12.23M $6.713M
YoY Change 82.21% 62.74%
FREE CASH FLOW
Cash From Operating Activities -$7.975M -$4.241M
Capital Expenditures $0.00 $2.000K
Free Cash Flow -$7.975M -$4.243M
YoY Change 87.96% -22.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000320017
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-33650
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
CALADRIUS BIOSCIENCES, INC.
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
22-2343568
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
110 Allen Road, 2nd Floor
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Basking Ridge
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07920
CY2021Q1 dei City Area Code
CityAreaCode
908
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
842-0100
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2021Q1 dei Trading Symbol
TradingSymbol
CLBS
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
59498958 shares
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28744000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16512000 USD
CY2021Q1 us-gaap Marketable Securities
MarketableSecurities
82767000 USD
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
18061000 USD
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2522000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
758000 USD
CY2021Q1 us-gaap Assets Current
AssetsCurrent
114033000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
35331000 USD
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
41000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2486000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
57000 USD
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
533000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
614000 USD
CY2021Q1 us-gaap Assets
Assets
114607000 USD
CY2020Q4 us-gaap Assets
Assets
36002000 USD
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2315000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1020000 USD
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2123000 USD
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4438000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3506000 USD
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
155000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
254000 USD
CY2021Q1 us-gaap Liabilities
Liabilities
4593000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
3760000 USD
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2020Q4 clbs Preferred Stock Liquidation Preference Share
PreferredStockLiquidationPreferenceShare
0.001 shares
CY2021Q1 clbs Preferred Stock Liquidation Preference Share
PreferredStockLiquidationPreferenceShare
0.001 shares
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q4 clbs Preferred Stock Shares Designated
PreferredStockSharesDesignated
825000 shares
CY2021Q1 clbs Preferred Stock Shares Designated
PreferredStockSharesDesignated
825000 shares
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
10000 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
10000 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
10000 shares
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
10000 shares
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59510038 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19389413 shares
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59498958 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19378333 shares
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
60000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
19000 USD
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
544601000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
458748000 USD
CY2021Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
11080 shares
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
11080 shares
CY2021Q1 us-gaap Treasury Stock Value
TreasuryStockValue
708000 USD
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
708000 USD
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-433613000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-425550000 USD
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-72000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-13000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
110268000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
32496000 USD
CY2021Q1 us-gaap Minority Interest
MinorityInterest
-254000 USD
CY2020Q4 us-gaap Minority Interest
MinorityInterest
-254000 USD
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
110014000 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
32242000 USD
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
114607000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
36002000 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5076000 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1499000 USD
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3010000 USD
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2558000 USD
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
8086000 USD
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
4057000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8086000 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4057000 USD
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
23000 USD
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
71000 USD
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
23000 USD
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
71000 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-8063000 USD
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-3986000 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
0 USD
CY2020Q1 us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
4000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-8063000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-3990000 USD
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42117000 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42117000 shares
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10623000 shares
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10623000 shares
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-8063000 USD
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-3986000 USD
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-59000 USD
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-59000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-8122000 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-3988000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
0 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
4000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8122000 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3992000 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
32242000 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-8063000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-59000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
413000 USD
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
85457000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
24000 USD
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
110014000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
20553000 USD
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-3986000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-2000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
419000 USD
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
16984000 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-8063000 USD
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-3986000 USD
CY2021Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
597000 USD
CY2020Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
567000 USD
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
16000 USD
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
15000 USD
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-323000 USD
CY2020Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-19000 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1763000 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-354000 USD
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-81000 USD
CY2020Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-233000 USD
CY2021Q1 clbs Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
834000 USD
CY2020Q1 clbs Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
-1443000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7975000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4241000 USD
CY2021Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
75911000 USD
CY2020Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0 USD
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
10821000 USD
CY2020Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
11104000 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-65090000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
11102000 USD
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
24000 USD
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2021Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
184000 USD
CY2020Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
148000 USD
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
85457000 USD
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
85297000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-148000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
12232000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6713000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16512000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14032000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28744000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20745000 USD
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amount of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.</span></div>
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 USD
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
73000 USD
CY2021Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States. Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</span></div>
CY2021Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
106997000 USD
CY2021Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
106924000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
30750000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
13000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
30737000 USD
CY2021Q1 us-gaap Cash
Cash
24157000 USD
CY2020Q4 us-gaap Cash
Cash
12676000 USD
CY2021Q1 us-gaap Marketable Securities
MarketableSecurities
82767000 USD
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
18061000 USD
CY2021Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
106924000 USD
CY2020Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
30737000 USD
CY2021Q1 us-gaap Available For Sale Securities Debt Maturities Remainder Of Fiscal Year Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis
106997000 USD
CY2021Q1 us-gaap Available For Sale Securities Debt Maturities Remainder Of Fiscal Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue
106924000 USD
CY2021Q1 us-gaap Available For Sale Securities Debt Maturities Rolling Year Two Through Five Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis
0 USD
CY2021Q1 us-gaap Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value
AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
0 USD
CY2021Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
106997000 USD
CY2021Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
106924000 USD
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1119000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1716000 USD
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
381000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
370000 USD
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
623000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
400000 USD
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2123000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2486000 USD
CY2021Q1 clbs Number Of Offices Under Operating Leases
NumberOfOfficesUnderOperatingLeases
2 office
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
492000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
574000 USD
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
536000 USD
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
624000 USD
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y7M6D
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.09625
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
312000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
239000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
27000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
578000 USD
CY2021Q1 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
42000 USD
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
536000 USD
CY2019Q1 clbs Aggregate Market Value Of Common Stock Non Affiliates
AggregateMarketValueOfCommonStockNonAffiliates
52800000 USD
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
65000000.0 USD
CY2021Q1 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
801148 shares
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1800000 USD
CY2020Q4 clbs Common Stock Warrants Shares
CommonStockWarrantsShares
2638355 shares
CY2020Q4 clbs Weighted Average Exercise Price Warrants Outstanding
WeightedAverageExercisePriceWarrantsOutstanding
2.18
clbs Weighted Average Remaining Contractual Termwarrantoutstanding
WeightedAverageRemainingContractualTermwarrantoutstanding
P4Y11M23D
CY2020Q4 clbs Aggregate Intrinsic Value Warrants Outstanding
AggregateIntrinsicValueWarrantsOutstanding
0 USD
CY2021Q1 clbs Warrants Granted
WarrantsGranted
19519393 shares
CY2021Q1 clbs Weighted Average Exercise Price Warrants Granted
WeightedAverageExercisePriceWarrantsGranted
2.90
CY2021Q1 clbs Warrants Exercised
WarrantsExercised
801148 shares
CY2021Q1 clbs Weighted Average Exercise Price Warrants Exercised
WeightedAverageExercisePriceWarrantsExercised
2.19
CY2021Q1 clbs Warrants Canceled
WarrantsCanceled
0 shares
CY2021Q1 clbs Sharesvestedandexpectedtovest
Sharesvestedandexpectedtovest
21356600 shares
CY2021Q1 clbs Weighted Average Exercise Price Warrants Canceled
WeightedAverageExercisePriceWarrantsCanceled
0
CY2021Q1 clbs Warrants Expired
WarrantsExpired
0 shares
CY2021Q1 clbs Weighted Average Exercise Price Warrants Expired
WeightedAverageExercisePriceWarrantsExpired
0
CY2021Q1 clbs Common Stock Warrants Shares
CommonStockWarrantsShares
21356600 shares
CY2021Q1 clbs Weighted Average Exercise Price Warrants Outstanding
WeightedAverageExercisePriceWarrantsOutstanding
2.84
CY2021Q1 clbs Weighted Average Remaining Contractual Termwarrantoutstanding
WeightedAverageRemainingContractualTermwarrantoutstanding
P4Y11M23D
CY2021Q1 clbs Aggregate Intrinsic Value Warrants Outstanding
AggregateIntrinsicValueWarrantsOutstanding
0 USD
CY2021Q1 clbs Weighted Average Exercise Price Warrants Vested And Expected To Vest
WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest
2.84
CY2021Q1 clbs Weighted Average Remaining Contractual Term Warrants Vestedand Expectto Vest
WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest
P4Y11M23D
CY2021Q1 clbs Aggregate Intrinsic Value Warrantsvestedandexpectedtovest
AggregateIntrinsicValueWarrantsvestedandexpectedtovest
0 USD
CY2021Q1 clbs Warrants Vested
WarrantsVested
21356600 shares
CY2021Q1 clbs Weighted Average Exercise Price Warrants Exercisable
WeightedAverageExercisePriceWarrantsExercisable
2.80
CY2021Q1 clbs Weighted Average Remaining Contractual Termwarrantsvested
WeightedAverageRemainingContractualTermwarrantsvested
P4Y11M23D
CY2021Q1 clbs Aggregate Intrinsic Value Warrantsvested
AggregateIntrinsicValueWarrantsvested
0 USD
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
597000 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
567000 USD
CY2017Q1 us-gaap Grants Receivable
GrantsReceivable
12200000 USD
CY2021Q1 us-gaap Grants Receivable
GrantsReceivable
8600000 USD
clbs Funding Of Grant Award Cash Received
FundingOfGrantAwardCashReceived
8200000 USD
CY2017Q2 clbs Funding Of Grant Award Cash Received
FundingOfGrantAwardCashReceived
5700000 USD
CY2017Q4 clbs Milestone Payment On Grant Award Cash Received
MilestonePaymentOnGrantAwardCashReceived
1900000 USD
CY2018Q1 clbs Progress Payment On Grant Award Cash Received
ProgressPaymentOnGrantAwardCashReceived
300000 USD
CY2019Q2 us-gaap Research And Development Arrangement With Federal Government Customer Funding To Offset Costs Incurred
ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
200000 USD
CY2020Q3 us-gaap Research And Development Arrangement With Federal Government Customer Funding To Offset Costs Incurred
ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
46000 USD
CY2021Q1 clbs Amortization Of Accrued Grant Funding Liability To Offset Expense
AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense
0.0 USD
CY2020Q1 clbs Amortization Of Accrued Grant Funding Liability To Offset Expense
AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense
700000 USD
CY2020Q4 clbs Market Capitalization Used In Net Operating Loss Analysis
MarketCapitalizationUsedInNetOperatingLossAnalysis
125000000 USD
CY2020 clbs Net Operating Loss Analysis Annual Limitation
NetOperatingLossAnalysisAnnualLimitation
3000000.0 USD

Files In Submission

Name View Source Status
0000320017-21-000067-index-headers.html Edgar Link pending
0000320017-21-000067-index.html Edgar Link pending
0000320017-21-000067.txt Edgar Link pending
0000320017-21-000067-xbrl.zip Edgar Link pending
clbs-20210331.htm Edgar Link pending
clbs-20210331.xsd Edgar Link pending
clbs-20210331_cal.xml Edgar Link unprocessable
clbs-20210331_def.xml Edgar Link unprocessable
clbs-20210331_htm.xml Edgar Link completed
clbs-20210331_lab.xml Edgar Link unprocessable
clbs-20210331_pre.xml Edgar Link unprocessable
clbs-ex311_20210331xq1.htm Edgar Link pending
clbs-ex32_20210331q1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending